KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Cash & Equivalents (2019 - 2026)

GoodRx Holdings' Cash & Equivalents history spans 7 years, with the latest figure at $261.8 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 41.6% to $261.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $261.8 million, a 41.6% decrease, with the full-year FY2025 number at $261.8 million, down 41.6% from a year prior.
  • Cash & Equivalents hit $261.8 million in Q4 2025 for GoodRx Holdings, down from $273.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for GDRX hit a ceiling of $990.5 million in Q1 2021 and a floor of $261.8 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $641.9 million across 5 years, with a median of $729.7 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: surged 933.49% in 2021 and later plummeted 46.69% in 2024.
  • Tracing GDRX's Cash & Equivalents over 5 years: stood at $941.1 million in 2021, then fell by 19.55% to $757.2 million in 2022, then decreased by 11.21% to $672.3 million in 2023, then tumbled by 33.31% to $448.3 million in 2024, then plummeted by 41.6% to $261.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for GDRX at $261.8 million in Q4 2025, $273.5 million in Q3 2025, and $281.3 million in Q2 2025.